Willis Towers Watson (WLTW) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
3 Feb, 2026Executive summary
Achieved strong Q4 and full-year organic revenue growth of 6% and 5%, respectively, with margin expansion driven by strategic focus, talent investment, and portfolio optimization.
Strategic acquisitions (Newfront, Cushon, FlowStone) and the TRANZACT divestiture enhanced the business mix and growth profile.
Digital platforms, data analytics, and AI-driven efficiency initiatives supported margin expansion.
Returned $1.65B to shareholders via share repurchases and paid $350M–$358M in dividends in 2025.
Net income for the year was $1.61B, rebounding from a prior year loss due to impairment charges.
Financial highlights
Q4 organic revenue growth of 6%, adjusted operating margin up 80 bps to 36.9%, and adjusted EPS of $8.12 (up 13% YoY excluding TRANZACT).
Full-year organic growth of 5%, adjusted operating margin up 130 bps to 25.2%, and adjusted EPS of $17.08 (up 13% YoY excluding TRANZACT).
Free cash flow for 2025 was $1.55B–$1.546B, up $279M YoY, with a margin of 15.9%.
Q4 income from operations rose 13% to $1.016B; full-year income from operations surged 256% to $2.234B.
Q4 revenue was $2.94B (down 3% YoY); full-year revenue was $9.71B (down 2%), primarily due to the TRANZACT sale.
Outlook and guidance
2026 guidance: mid-single-digit organic growth, continued margin and free cash flow expansion.
Expecting ~100 bps annual margin expansion in Risk & Broking and incremental expansion in Health, Wealth & Career.
Foreign exchange expected to be a $0.30 tailwind to adjusted EPS in 2026.
At least $1B allocated to share repurchases in 2026, with ongoing evaluation of M&A opportunities.
Newfront acquisition expected to be ~$0.10 dilutive to adjusted EPS in 2026, with $250M post-close revenue and ~26% adjusted EBITDA margin.
Latest events from Willis Towers Watson
- Q2 2024 delivered 6% organic growth, margin expansion, and raised 2024 guidance.WLTW
Q2 20242 Feb 2026 - Q3 saw 6% revenue growth, margin gains, and a $1.67B loss from TRANZACT sale charges.WLTW
Q3 202417 Jan 2026 - Sustained organic growth and margin expansion driven by innovation, efficiency, and portfolio optimization.WLTW
CMD 202412 Jan 2026 - 5% organic growth, margin gains, $473M savings, and $1.5B buyback planned for 2025.WLTW
Q4 20248 Jan 2026 - $1.3B acquisition leverages advanced tech and talent for $35M in synergies and U.S. growth.WLTW
M&A Announcement10 Dec 2025 - 2025 AGM to vote on directors, auditors, executive pay, share issuance, and pre-emption rights.WLTW
Proxy Filing1 Dec 2025 - Annual meeting covers director elections, pay, and auditor ratification.WLTW
Proxy Filing1 Dec 2025 - 5% organic growth and margin expansion offset TRANZACT sale; net income up 23%.WLTW
Q1 20251 Dec 2025 - Q2 2025 saw 5% organic growth, 20% EPS rise, and robust margin expansion amid strong segment results.WLTW
Q2 20255 Nov 2025